With 0.67 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.04 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $46.7499 whereas the lowest price it dropped to was $44.24. The 52-week range on SMLR shows that it touched its highest point at $81.56 and its lowest point at $21.77 during that stretch. It currently has a 1-year price target of $98.00. Beta for the stock currently stands at 1.35.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SMLR was up-trending over the past week, with a rise of 16.12%, but this was up by 42.59% over a month. Three-month performance surged to 38.61% while six-month performance fell -9.88%. The stock lost -16.24% in the past year, while it has gained 39.60% so far this year. A look at the trailing 12-month EPS for SMLR yields -2.61 with Next year EPS estimates of -0.23. For the next quarter, that number is -0.27. This implies an EPS growth rate of -166.67% for this year and 93.13% for next year.
Float and Shares Shorts:
At present, 13.79 million SMLR shares are outstanding with a float of 11.15 million shares on hand for trading. On 2025-06-13, short shares totaled 2.6 million, which was 1980.9999999999998 higher than short shares on 1747267200. In addition to Dr. Douglas Murphy-Chutorian M.D. as the firm’s CEO, President & Director, Ms. Renae Cormier serves as its CFO, Principal Accounting Officer, Head of Corp. Communications & Bus. Strategy and Secretary.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, SMLR reported revenue of $8835000.0 and operating income of -$1351000.0. The EBITDA in the recently reported quarter was -$1227000.0 and diluted EPS was -$6.74.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SMLR since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $2.23 being high and $2.23 being low. For SMLR, this leads to a yearly average estimate of $2.23.
